Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program

Rhea-AI Summary

Arch Therapeutics, Inc. (OTCQB: ARTH) announced a new interview featuring Dr. Christopher Gauland as part of its Experts in Wound Care Program. In the interview, Dr. Gauland provides insights on treating diabetic foot ulcers (DFUs) and discusses the effectiveness of AC5^® Advanced Wound System in improving patient outcomes. The discussion highlights the severity of DFUs, where 48% remain unhealed within a year and 17% lead to amputation. The interview is available online, contributing to Arch's mission of advancing wound care through expert insights.

Positive

• Dr. Gauland's interview showcases the effectiveness of AC5^® in treating DFUs.
• Arch expands its Experts in Wound Care Program, enhancing its marketing outreach.
• Growing body of case studies supporting AC5^® highlights its potential impact on patient limb salvage.

Negative

• None.

Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5^® Advanced Wound System

FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that it has added a key opinion leader (KOL) interview to its Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care.

The interview, “Preventing Diabetic Foot Ulcers and How AC5^® Advanced Wound System Can Help”, is conducted with key opinion leader, Dr. Christopher Gauland, Podiatric Surgery Specialist at Eastern Carolina Foot & Ankle Specialists in North Carolina, and world-renowned lecturer on topics regarding foot and ankle infection, wounds, and limb salvage.

Dr. Gauland discusses challenges, infections, and healing of diabetic foot ulcers (DFU’s) as well as using AC5^® Advanced Wound System to support better outcomes in patients with DFUs. The interview with Dr. Gauland is available at https://bit.ly/3d3PH9Y.

The event has been added to the Company’s Experts in Wound Care video channel, which can be tracked and tweeted by followers using the hashtag: #ExpertsInWoundCare.

“Studies have shown that 48% of diabetic foot ulcers remain unhealed within a 12-month period and approximately 17% result in amputation. Arch is honored to have key opinion leaders such as Dr. Gauland sharing their experiences with using AC5^® Advanced Wound System on DFU’s,” stated Terry Norchi, MD, Chief Executive Officer of Arch Therapeutics. “Expert testament, along with a growing body of case studies, continues to illustrate the potential impact that AC5^® Advanced Wound System can have on healing outcomes, patient limb salvage, and savings to the healthcare system,” concluded Dr. Norchi.

About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5^® Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.^1,2

---

¹ AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
² AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5^® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com

or

Michael Abrams
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2333
Email: mabrams@archtherapeutics.com

FAQ

What recent updates did Arch Therapeutics (ARTH) announce in December 2021?

Arch Therapeutics announced an interview with Dr. Christopher Gauland discussing diabetic foot ulcers and the use of AC5^® Advanced Wound System.

What is the significance of AC5^® Advanced Wound System according to Dr. Gauland?

Dr. Gauland emphasizes AC5^®’s potential to improve healing outcomes for diabetic foot ulcers, where a significant percentage remain unhealed or lead to amputation.

How does Arch Therapeutics (ARTH) contribute to wound care?

Arch Therapeutics is focused on marketing innovative self-assembling wound care devices like the AC5^® Advanced Wound System to enhance healing and patient care.

Where can I find the interview with Dr. Gauland regarding AC5^®?

The interview is available through Arch Therapeutics' Experts in Wound Care video channel and can be accessed via their website.